Endocrine Archives

MammaPrint UltraLow from FLEX Study, Graham et al., SABCS 2023 Abstract

SABCS 2023, PO1-02-11 Authors: Cathy Graham et al.

Read More

Karen Guzdzial2024-02-16T06:55:06-08:00December 14th, 2023|Endocrine, Evidence, FLEX|

LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- breast cancer at very low risk of metastasis

Publication: ASCO 2023, Abstract TPS615 Authors: Elise Deluche, Stefan Michiels, Daniele Fric, Christophe Perrin, Caroline Bailleux, Thomas Bachelot, Pascal Ko Kivok Yun, Gaetan De Rauglaudre, Marie-Ange Mouret-Reynier, Romauld Le Scodan, Ines Vaz-Luis, Magali Lacroix-Triki, Clara Guyonneau, Fabrice Andre

Read More

Joel Adamich2024-02-16T07:00:39-08:00June 18th, 2023|Endocrine, Evidence, LESS|

FOCUS Trial: Validation of MammaPrint for ≥ 70yrs w/ UltraLow risk of distant recurrence

J Geriatr Oncol. 2022 Nov;13(8):1172-1177 Authors: Noordhoek et al.

Read More

Karen Guzdzial2024-03-26T09:06:34-07:00November 26th, 2022|Endocrine, Evidence, FOCUS, Other, Validation|

IKA Trial: MammaPrint UltraLow & Limited Systemic Endocrine Overtreatment

IKA Trial, Breast Cancer Res Treat, 2022; 194(2): 265-278 Authors: Opdam, et al.

Read More

Karen Guzdzial2024-03-26T08:57:48-07:00May 19th, 2022|Endocrine, Evidence, IKA|

MINDACT: Outcomes of any adjuvant systemic treatment in ESBC

Annals of Oncology, Volume 33, Issue 3, March 2022, Pages 310-320 Authors: Lopes Cardozo et al.

Read More

Karen Guzdzial2024-03-26T09:59:36-07:00March 26th, 2022|Adjuvant, Endocrine, Evidence, MINDACT, MINDACT|

MINDACT Trial: Outcome of Patients with UltraLow Risk, JCO 2022

Journal of Clinical Oncology, Volume 40, Number 12, January 21, 2022 Authors: Audeh et al.

Read More

Karen Guzdzial2024-03-26T09:54:43-07:00January 26th, 2022|Adjuvant, Endocrine, Evidence, MINDACT, MINDACT|

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
Gallery
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

Endocrine, Evidence, MammaPrint, STO-3

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS: Laura J. Esserman, MD, Read More

kevin2024-03-25T08:58:29-07:00November 2nd, 2017|Endocrine, Evidence, MammaPrint, STO-3|

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk
Gallery
Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

Endocrine, Evidence, MammaPrint, STO-3

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

PUBLICATION: Breast Cancer Res Treat (2017) 166: 593. https://doi.org/10.1007/s10549-017-4428-9. AUTHORS: Read More

kevin2024-03-25T08:59:17-07:00November 1st, 2017|Endocrine, Evidence, MammaPrint, STO-3|

Additional Value of the 70-gene Signature and Levels of ER and PR for the Prediction of Outcome in Tamoxifen-Treated, ER-Positive Breast Cancer
Additional Value of the 70-gene Signature and Levels of ER and PR for the Prediction of Outcome in Tamoxifen-Treated, ER-Positive Breast Cancer

Endocrine, Evidence, MammaPrint

Additional Value of the 70-gene Signature and Levels of ER and PR for the Prediction of Outcome in Tamoxifen-Treated, ER-Positive Breast Cancer

PUBLICATION: The Breast. 2012 Dec;21(6):769-78. doi: 10.1016/j.breast.2012.04.010. Epub 2012 Jun Read More

kevin2024-03-25T10:49:46-07:00December 1st, 2012|Endocrine, Evidence, MammaPrint|

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

Additional Value of the 70-gene Signature and Levels of ER and PR for the Prediction of Outcome in Tamoxifen-Treated, ER-Positive Breast Cancer

Kenyon Sweeney

Christy Garcia

PROF. LAURA VAN ‘T VEER, PhD

ROOPOM BANERJEE